SCHEMBL5072436

SCHEMBL5072436

O=C1C=CC(=O)N1Cc1ccc(O)c(O)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 4/20 0.63
▸ FAAH O00519 2/20 0.63
▸ PTGS1 P23219 2/20 0.53
▸ PTGS2 P35354 1/20 0.53
▸ GSK3A P49840 2/20 0.52
▸ GSK3B P49841 2/20 0.52
▸ ERCC1 P07992 1/20 0.49
▸ ERCC4 Q92889 1/20 0.49
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA4 P22748 1/20 0.48
▸ CA6 P23280 1/20 0.48
▸ KDM4E B2RXH2 3/20 0.46
▸ MAPT P10636 3/20 0.46
▸ GAA P10253 2/20 0.46
▸ APEX1 P27695 2/20 0.46
▸ THPO P40225 2/20 0.46
▸ HIF1A Q16665 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32665316 0.84 MGLL (0.57) MGLLFAAHPTGS1PTGS2GSK3A
SCHEMBL6345642 0.84 MGLL (0.57) MGLLFAAHPTGS1PTGS2GSK3A
SCHEMBL29693886 0.81 KDM4E (0.56) MGLLPTGS1GSK3AGSK3BCA1
SCHEMBL2435701 0.79 CA1 (0.53) PTGS1ERCC1ERCC4CA1CA2
SCHEMBL146412 0.79 MGLL (1.00) MGLLFAAHPTGS1PTGS2GSK3A
SCHEMBL4804503 0.78 MGLL (0.78) MGLLFAAHPTGS1PTGS2GSK3A
SCHEMBL28797331 0.76 MGLL (0.49) MGLLFAAHPTGS1PTGS2GSK3A
SCHEMBL7224603 0.76 MGLL (0.60) MGLLFAAHPTGS1PTGS2GSK3A
SCHEMBL140975 0.75 MGLL (0.72) MGLLFAAHPTGS1PTGS2GSK3A
SCHEMBL32665181 0.74 KDM4E (0.47) MGLLFAAHKDM4EGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
WO-2023028338-A2 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2023-03-02 — — WO disclosed
CN-115066438-A ASGPR binding compounds for degrading extracellular proteins 阿维拉治疗公司 2022-09-16 — — CN disclosed
WO-2008125787-A1 METHOD FOR PREPARING A CATALYST AND USE THEREOF IN A CONTINUOUS METHOD FOR THE TRANSESTERIFICATION OF (METH)ACRYLIC ESTERS ARKEMA FRANCE (FR) 2008-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A MGLL 894/4885FAAH 2351/4885PTGS1 2593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback